About
Accelmed is a global group of funds investing in HealthTech companies (medical device, diagnostics and digital health) across all stages. It currently invests through two separate arms: Accelmed Partners a US-based lower market private equity HealthTech fund, focused on Buyout and Growth Investments in commercial HealthTech (>$10M LTM) companies; and, Accelmed Ventures an Israel based venture fund, focused on pre-commercialization and early revenue HealthTech Opportunities. Accelmed Partners is acquiring commercial HealthTech companies and fostering significant value creation by supporting management teams, driving innovation, providing growth capital and potentially integrating innovative add-on technologies, largely from Israel. Accelmed Partners targets equity investments of $10-50M per transaction. Accelmed Ventures aims to create successful medical device and digital health companies by using its deep expertise, extensive network and proven track record. It focuses on medical devices and digital health companies with exceptional leading teams; innovative solutions addressing unmet needs in major chronic disease areas such as neurodegenerative, oncology, metabolic and cardiovascular diseases; and companies with a proven clinical concept and/or a proven business model.
Portfolio · 19
Investment activity
9 portfolio exits on record.
Portfolio by sector
Funds · 4
- 4 — $400M Mar 2021
- 3 — $100M Oct 2019
- 2 — $130M Jan 2016
- 1 — $100M Jan 2011
Q&A
- What is Accelmed's primary investment focus?
- Accelmed is a global group of funds investing in HealthTech companies, specifically medical devices, diagnostics, and digital health, across all stages.
- What was a recent notable exit for Accelmed?
- In May 2026, Accelmed saw an exit with EndoSpan being acquired by Artivion for $335M. Another notable exit was BioProtect, acquired by Almeda Ventures for $200M in January 2026.
- Which portfolio company did Accelmed exit in March 2025?
- Accelmed exited SoniVie in March 2025 when it was acquired by Boston Scientific for $400M.
- What is the most recent fund raised by Accelmed?
- Accelmed closed Fund 4 in March 2021, raising $400M.
- Can you name a recent acquisition of an Accelmed portfolio company in the cybersecurity sector?
- In July 2025, Cynerio, a cybersecurity for healthcare providers, was acquired by Axonius for $180M, representing an exit for Accelmed.
- What is Accelmed's investment strategy for its US-based fund?
- Accelmed Partners, its US-based fund, focuses on Buyout and Growth Investments in commercial HealthTech companies with over $10M LTM, targeting equity investments of $10-50M per transaction.
- What is the focus of Accelmed Ventures, its Israel-based fund?
- Accelmed Ventures, based in Israel, focuses on pre-commercialization and early revenue HealthTech opportunities, specifically in medical devices and digital health companies with innovative solutions for major chronic disease areas.
- Who are the co-founders of Accelmed?
- Accelmed was co-founded by Mori Arkin and Dr. Uri Geiger.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | accelmed.com/ |
|---|---|
| linkedin.com/company/40854016 |
Identifiers & details
| Founded | 2009 |
|---|
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | accelmed.com |
|---|